Even if the role of serum KL-6 in ARDS and in COVID-19 is still uncertain, Kost-Alimova et al. [18] proposed R406, the active metabolite of Fostamatinib, as a compound for the reduction of KL-6 levels in lung epithelium in the setting of COVID ARDS. This evidence concerns the gene MUC1 and COVID-19.